Asset Details
Do you wish to reserve the book?
Deploying the high-throughput virtual screening (HTVS) approach for the identification of new lactate dehydrogenase (LDH) inhibitors with anticancer assets
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Deploying the high-throughput virtual screening (HTVS) approach for the identification of new lactate dehydrogenase (LDH) inhibitors with anticancer assets
Do you wish to request the book?
Deploying the high-throughput virtual screening (HTVS) approach for the identification of new lactate dehydrogenase (LDH) inhibitors with anticancer assets
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Deploying the high-throughput virtual screening (HTVS) approach for the identification of new lactate dehydrogenase (LDH) inhibitors with anticancer assets
2026
Overview
The tumor cells frequently rely on glycolysis to produce adenosine 5′-triphosphate (ATP), even when sufficient oxygen is available to allow oxidative phosphorylation (the Warburg effect). In these malignancies, the breakdown of glucose to pyruvate, instead of reaching the mitochondria, is transformed to lactate by an enzyme called lactate dehydrogenase (LDH) and then expelled by the cells, further fuelling the tumour microenvironment (TME). LDH facilitates the translation of pyruvate to lactate, hence replenishing the required NAD + equivalents for the ongoing glycolysis process. Having a pivotal role in cancer cells’ prognosis and survival, and affecting the TME. To date, no inhibitors have yet been approved against the LDH. However, numerous clinical trials are ongoing, and results are yet to be awaited. Considering the existing gap, we present herein a high-throughput virtual screening (HTVS) approach to identify new compounds that effectively inhibit LDH activity. We generated the pharmacophore model based on 28 LDH enzyme inhibitors from previous literature. The model was used to screen 500,000 ligands in addition to their molecular docking and drug-likeness filtering. The analysis led to the identification of 5 hits, which were further subjected to the MD simulations. Further considering the outcome of molecular dynamics results, we selected ligands
15
and
422
to corroborate their anticancer potential via inhibiting the LDH enzyme. The biological validation revealed that both ligands, 15 and 422, possess IC
50
values of 147.34 and 206.35 nM, respectively, against LDH. The anticancer potential analysis of DU-145 and PC-3 also established their anticancer properties, and both compounds were found to marginally elevate oxidative stress, change mitochondrial membrane potential, and induce apoptosis in DU-145 cells.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 631/154
/ 631/45
/ 631/67
/ Antineoplastic Agents - chemistry
/ Antineoplastic Agents - pharmacology
/ Enzyme Inhibitors - chemistry
/ Enzyme Inhibitors - pharmacology
/ Enzymes
/ High-Throughput Screening Assays - methods
/ Humanities and Social Sciences
/ Humans
/ L-Lactate Dehydrogenase - antagonists & inhibitors
/ L-Lactate Dehydrogenase - chemistry
/ L-Lactate Dehydrogenase - metabolism
/ Ligands
/ Molecular Docking Simulation
/ Molecular Dynamics Simulation
/ Proteins
/ Science
/ Software
/ Tumors
